- Hims & Hers Health said Wednesday it will offer five compounded peptide and longevity treatments made in the U.S. as the first rollout of its Peptides+ platform: sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, CNBC reported.
- None of the specific compounded products are approved by the Food and Drug Administration, though Hims said they are authorized by law and made by state-licensed and inspected pharmacies.
- More than 10,000 people signed up for the early access list within 15 days of its launch in late October, a company spokesperson said.
- The launch follows an October Health and Human Services policy under which the FDA will not take enforcement action against licensed pharmacies and physicians that compound six unapproved peptides while formal rules are reviewed.
What Happened?
Hims plans to add more U.S.-made peptides over time, including BPC-157 and TB-500, unapproved peptides that have mostly been studied in animals. Patients start with an assessment by a licensed provider trained in peptide therapies, and those with serious illnesses such as cardiovascular, liver and kidney disease will not be candidates for now. Chief medical officer Dr. Anant Vinjamoori acknowledged uncertainty: “We don’t have all of this data that we’re used to having with compounds like this.” HHS Secretary Robert F. Kennedy Jr. has supported broader access to peptides. Hims acquired a California peptide manufacturing facility in February 2025.
Why It Matters?
Peptides, which have exploded in popularity among fitness and longevity enthusiasts, give Hims a new product line, and the eased federal stance opens the door for compounders to sell them. The risk is regulatory and clinical: experts quoted by CNBC said most peptides lack robust human trials and that dosing has not been established. The FDA said in August it had received reports of at least 30 patients who had adverse events after compounded IV glutathione from various pharmacies. Any reversal of the HHS policy or safety problems could hit the business.
What’s Next?
Watch how quickly Hims adds BPC-157 and TB-500, whether formal FDA rules on the six peptides change the legal footing, and whether the company gives sign-up or revenue figures for Peptides+ in its next earnings report.
Affected Tickers and Coins: HIMS
Source: CNBC












